| Website | valderm.dk |
| Category | BioTech |
| Phone | 45-30138581 |
| darko@valderm.dk | |
| Employees |
| TOTAL | $3.37M |
| FUNDING TOTAL | $3.37M |
| Series A, 8/07 Seed Capital | $3.37M |
Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyperproliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented.
